Skip to main content

Table 1 Univariate survival analysis

From: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

   Univariate
Covariate Baseline Coefficient HR 95,0% CI for HR p-value
Grade 2 Grade 1 2.047 7.742 (1.012-59.228) 0.049
Grade 3 Grade 1 2.955 19.193 (2.455-150.003) 0.005
T3 T2 -0.18 0.982 (0.128-7.517) 0.986
T4 T2 0.569 1.767 (0.228-13.717) 0.586
N1 N0 0.696 2.007 (0.696-5.783) 0.197
N2 N0 0.759 2.136 (0.714-6.383) 0.174
M M0 0.606 1.833 (0.683-4.918) 0.229
Stage 3 Stage2 0.852 2.344 (0.686-8.008) 0.174
Stage 4 Stage2 1.088 2.970 (0.708-12.463) 0.137
ER ER positive 1.335 3.800 (1.566-9.223) 0.003
PR PR positive 0.620 1.859 (0.800-4.318 0.149
ErbB2 ErbB2 positive 0.965 2.624 (0.931-7.395) 0.068
TP53 Wild type TP53 1.230 3.423 (1.553-7.542) 0.002
ABCB1 _2 ABCB1 _2 Methylated 1.147 3.147 (1.389-7.133) 0.006
FOXC1 _3 FOXC1 _3 Methylated 1.030 2.802 (1.127-6.969) 0.027
GSTP1 _2 GSTP1 _2 Methylated 1.215 3.369 (1.280-8.868) 0.014
  1. Univariate survival analysis using the Cox regression model using the categorical methylation data. Positive hazard ratios indicate an increased risk of dying from breast cancer and are calculated for the different covariates in reference to the baseline as given in the 2nd column.